LON:ETX e-therapeutics (ETX) Share Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free ETX Stock Alerts GBX 12.46 -0.42 (-3.26%) (As of 05:39 AM ET) Add Compare Share Share Today's Range 12.46▼ 1350-Day Range 11.50▼ 18.1352-Week Range 8▼ 24Volume113,976 shsAverage Volume346,552 shsMarket Capitalization£72.78 millionP/E RatioN/ADividend Yield3.35%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get e-therapeutics alerts: Email Address Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About e-therapeutics Stock (LON:ETX)e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.Read More ETX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETX Stock News HeadlinesMarch 16, 2024 | msn.comAquestive maps out FDA approval for sublingual anaphylaxis drugMarch 15, 2024 | americanbankingnews.come-therapeutics (LON:ETX) Shares Cross Below Two Hundred Day Moving Average of $12.41March 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… January 3, 2024 | finance.yahoo.comWe're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash WiselyDecember 27, 2023 | msn.comMedical innovator e-therapeutics to stop trading on US-based marketNovember 13, 2023 | markets.businessinsider.comEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discoveryOctober 30, 2023 | businesswire.comEvecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot EhrichOctober 26, 2023 | proactiveinvestors.comE-therapeutics bolsters generative AI integration and strategic...March 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.September 28, 2023 | benzinga.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 28, 2023 | marketwatch.comQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldSeptember 20, 2023 | proactiveinvestors.come-therapeutics appoints new CFOJuly 13, 2023 | uk.finance.yahoo.comETX.L - e-Therapeutics plcJune 8, 2023 | wsj.comElicio Therapeutics Inc.May 23, 2023 | businesswire.comAgeX Therapeutics Announces Appeal of NYSE American DeterminationMay 10, 2023 | businesswire.comRapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian MarketMay 10, 2023 | marketwatch.comDelix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001May 6, 2023 | marketwatch.comAcute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,PfizerMay 4, 2023 | marketwatch.comE-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D CostsMay 4, 2023 | finance.yahoo.come-Therapeutics working to capitalise on AI "blindside"April 28, 2023 | markets.businessinsider.comRelief Therapeutics Announces Results of Extraordinary General Meeting of ShareholdersApril 28, 2023 | marketwatch.com8-K: Seres Therapeutics, Inc.March 30, 2023 | marketwatch.comAquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film to Additional Global MarketsFebruary 26, 2023 | uk.finance.yahoo.come-Therapeutics plc (ETX.L)January 5, 2023 | benzinga.comAkero Therapeutics Stock (NASDAQ:AKRO), Quotes and News SummaryDecember 8, 2022 | markets.businessinsider.comAkero Therapeutics Announces Breakthrough Therapy Designation For EfruxiferminSeptember 30, 2022 | proactiveinvestors.come-therapeutics raises £13.5mln via a direct subscription by funds run by M&GSee More Headlines Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/17/2020Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ETX CUSIPN/A CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-10,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295,000.00 Price / Sales255.03 Cash FlowGBX 2.54 per share Price / Cash Flow5.07 Book ValueGBX 5 per share Price / Book2.58Miscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£75.23 million OptionableNot Optionable Beta0.48 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Ahmad Ali Mortazavi (Age 53)CEO & Director Comp: $270kMr. Timothy BrethertonCFO, Director of Finance & Operations and Company SecretaryDr. Laura Roca-Alonso Ph.D.Chief Operating OfficerMr. Alan Whitmore B.Sc.Ph.D., Chief Scientific OfficerMr. Ankit SharmaHead of Software EngineeringMr. Graham CraggsHead of Therapeutic DiscoveryMore ExecutivesKey CompetitorsOpen OrphanLON:ORPHRedx PharmaLON:REDXMereo BioPharma Group plc (MPH.L)LON:MPHFaron Pharmaceuticals OyLON:FARNScancellLON:SCLPView All CompetitorsInsidersTrevor Mervyn JonesBought 91,325 shares on 1/9/2024Total: £730,600.00 ($8.00/share)Trevor Mervyn JonesBought 34,830 shares on 7/6/2023Total: £766,260.00 ($22.00/share)View All Insider Transactions ETX Stock Analysis - Frequently Asked Questions How have ETX shares performed in 2024? e-therapeutics' stock was trading at GBX 8.24 at the beginning of the year. Since then, ETX shares have increased by 51.2% and is now trading at GBX 12.46. View the best growth stocks for 2024 here. How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) released its earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.03. What other stocks do shareholders of e-therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY). How do I buy shares of e-therapeutics? Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ETX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Companytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.